A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects

NCT05459285 · Completed

Last updated 2026-05-28

This clinical trial compares how two diabetes medications, 14028 Injection and TRULICITY®, are absorbed into the bloodstream in healthy Chinese adults.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 68 people

Who can join Ages 18–45 · male only Healthy volunteers accepted.

Timeline Started 2022-05 · est. completion 2022-07

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05459285 ↗

Description as written by the study sponsor.

To evaluate the pharmacokinetics similarity between the 14028 injection produced by Sunshine Lake Pharma Co., Ltd. and dulaglutide injection (TRULICITY®) produced by Eli Lilly and Company for single dose in healthy male subjects, as well as to evaluate the similarity of the safety and immunogenicity between 14028 Injection and TRULICITY® in Healthy Subjects

Treatments tested

14028 injection Biologic

14028 injection, single dose, s.c. injection
dulaglutide injection also known as TRULICITY® Biologic

dulaglutide injection(TRULICITY®), single dose, s.c. injection

Main thing measured	Maximum (peak) plasma drug concentration(Cmax)
Sponsor	Sunshine Lake Pharma Co., Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05459285 ↗